GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViroGates AS (OCSE:VIRO) » Definitions » ROE % Adjusted to Book Value

ViroGates AS (OCSE:VIRO) ROE % Adjusted to Book Value : -20.77% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ViroGates AS ROE % Adjusted to Book Value?

ViroGates AS's ROE % for the quarter that ended in Sep. 2024 was -108.63%. ViroGates AS's PB Ratio for the quarter that ended in Sep. 2024 was 5.23. ViroGates AS's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -20.77%.


ViroGates AS ROE % Adjusted to Book Value Historical Data

The historical data trend for ViroGates AS's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroGates AS ROE % Adjusted to Book Value Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -14.80 -6.27 -2.66 -7.11 -32.06

ViroGates AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.57 -47.83 -30.31 -29.77 -20.77

Competitive Comparison of ViroGates AS's ROE % Adjusted to Book Value

For the Medical Devices subindustry, ViroGates AS's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroGates AS's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where ViroGates AS's ROE % Adjusted to Book Value falls into.


;
;

ViroGates AS ROE % Adjusted to Book Value Calculation

ViroGates AS's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-73.10% / 2.28
=-32.06%

ViroGates AS's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-108.63% / 5.23
=-20.77%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ViroGates AS ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of ViroGates AS's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


ViroGates AS Business Description

Traded in Other Exchanges
N/A
Address
Banevaenget 13, Birkerod, DNK, DK-3460
ViroGates AS is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.

ViroGates AS Headlines

No Headlines